

11 July 2024

Treatment of renal cell carcinoma

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

- **Avelumab + Axitinib** <5
- **Axitinib** <5
- **Cabozantinib** <5
- **Everolimus** <5
- **Lenvatinib + Everolimus** <5
- **Lenvatinib + Pembrolizumab** 6
- **Nivolumab monotherapy** 13
- **Nivolumab + Cabozantinib** 19
- **Nivolumab + Ipilimumab** <5
- **Pazopanib** <5
- **Pembrolizumab monotherapy** 35
- **Pembrolizumab + Axitinib** <5
- **Radiotherapy only** <5
- **Sunitinib** <5
- **Temsirolimus** <5
- **Tivozanib** <5
- **Other active systemic anti-cancer therapy**
- **Palliative care only** Information not available from RISOH

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

44 performed between April 24 and 8th July

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- **Nivolumab (monotherapy)** 5
- **Nivolumab + Ipilimumab** <5
- **Nivolumab + Cabozantinib** <5
- **Lenvatinib + Pembrolizumab** <5
- **Avelumab + Axitinib** <5

11 July 2024

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Trials open to recruitment:

There are no renal cell carcinoma trials currently open to recruitment.

Trials in follow up:

Trial Title:	Recruitment
A prospective observational international study of cabozantinib tablets in combination with nivolumab as first-line treatment of advanced renal cell carcinoma in adults	Recruited 6 patients Trial closed 19 April 2024

Trials in set-up:

There are no trials specific to renal cell carcinoma currently in set-up, but renal cell carcinoma patients may be considered for participation in the following trials:

ModiFY A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian or Renal Cancer	Due to open 3Q24
Pan Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade	Trial feasibility being assessed